公开(公告)号：US20120225859A1

公开(公告)日：2012-09-06

申请号：US13471111

申请日：2012-05-14

Applicant: Matthew BURGER ,  Zhi-Jie NI ,  Sabina PECCHI ,  Gordana ATALLAH ,  Sarah BARTULIS ,  Kelly FRAZIER ,  Aaron SMITH ,  Joelle VERHAGEN ,  Yanchen ZHANG ,  Allan WAGMAN ,  Simon NG ,  Keith PFISTER ,  Daniel POON ,  Alicia LOUIE ,  Teresa PICK ,  Paul BARSANTI ,  Edwin IWANOWICZ ,  Wendy FANTL ,  Thomas HENDRICKSON ,  Mark KNAPP ,  Hanne MERRITT ,  Charles VOLIVA ,  Marion WIESMANN ,  Xiaohua XIN

Inventor： Matthew BURGER ,  Zhi-Jie NI ,  Sabina PECCHI ,  Gordana ATALLAH ,  Sarah BARTULIS ,  Kelly FRAZIER ,  Aaron SMITH ,  Joelle VERHAGEN ,  Yanchen ZHANG ,  Allan WAGMAN ,  Simon NG ,  Keith PFISTER ,  Daniel POON ,  Alicia LOUIE ,  Teresa PICK ,  Paul BARSANTI ,  Edwin IWANOWICZ ,  Wendy FANTL ,  Thomas HENDRICKSON ,  Mark KNAPP ,  Hanne MERRITT ,  Charles VOLIVA ,  Marion WIESMANN ,  Xiaohua XIN

IPC: A61K31/5377 ,  C07D413/14 ,  C12N5/07 ,  A61K31/553 ,  A61K31/541 ,  C07D471/08 ,  A61P35/00 ,  A61K31/538

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Abstract translation: 磷脂酰肌醇（PI）3-激酶抑制剂化合物（I），其药学上可接受的盐和前药; 单独或与至少一种另外的治疗剂组合的新化合物与药学上可接受的载体的组合物; 以及单独或与至少一种另外的治疗剂组合的新化合物在预防或治疗以生长因子，蛋白质丝氨酸/苏氨酸激酶和磷脂激酶异常活性为特征的增殖性疾病中的用途。

公开(公告)号：US08173689B2

公开(公告)日：2012-05-08

申请号：US12387946

申请日：2009-05-08

Applicant: James C. Sutton ,  Marion Wiesmann

Inventor： James C. Sutton ,  Marion Wiesmann

IPC: A61K31/423 ,  A61K31/444 ,  A61K31/428 ,  A61K31/506 ,  A61P19/10

CPC classification number: C07D413/12 ,  C07D417/12

Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

Abstract translation: 公开了苯并恶唑和苯并噻唑化合物及其立体异构体，互变异构体，溶剂合物，氧化物，酯和前药及其药学上可接受的盐。 还公开了单独或与至少一种另外的治疗剂组合的化合物与药学上可接受的载体的组合，以及化合物单独或与至少一种另外的治疗剂组合的用途。 这些实施方案可用于抑制细胞增殖，抑制肿瘤的生长和/或复分解，治疗或预防癌症，治疗或预防退行性骨疾病如类风湿性关节炎和/或抑制分子如CSF-1R。

公开(公告)号：US20100249126A1

公开(公告)日：2010-09-30

申请号：US12161537

申请日：2007-01-22

Applicant: Matthew Burger ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Gordana Atallah ,  Sarah Bartulis ,  Kelly Frazier ,  Aaron Smith ,  Joelle Verhagen ,  Yanchen Zhang ,  Allan Wagman ,  Simon Ng ,  Keith Pfister ,  Daniel J. Poon ,  Alicia Louie ,  Teresa Pick ,  Paul Barsanti ,  Edwin Iwanowicz ,  Wendy Fantl ,  Thomas Hendrickson ,  Mark Knapp ,  Hanne Meritt ,  Charles Voliva ,  Marion Wiesmann ,  Xiahua Xin

Inventor： Matthew Burger ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Gordana Atallah ,  Sarah Bartulis ,  Kelly Frazier ,  Aaron Smith ,  Joelle Verhagen ,  Yanchen Zhang ,  Allan Wagman ,  Simon Ng ,  Keith Pfister ,  Daniel J. Poon ,  Alicia Louie ,  Teresa Pick ,  Paul Barsanti ,  Edwin Iwanowicz ,  Wendy Fantl ,  Thomas Hendrickson ,  Mark Knapp ,  Hanne Meritt ,  Charles Voliva ,  Marion Wiesmann ,  Xiahua Xin

IPC: A61K31/5377 ,  C07D413/14 ,  A61P35/00

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Abstract translation: 磷脂酰肌醇（PI）3-激酶抑制剂化合物（I），其药学上可接受的盐和前药; 单独或与至少一种另外的治疗剂组合的新化合物与药学上可接受的载体的组合物; 以及单独或与至少一种另外的治疗剂组合的新化合物在预防或治疗以生长因子，蛋白质丝氨酸/苏氨酸激酶和磷脂激酶异常活性为特征的增殖性疾病中的用途。

公开(公告)号：US20090281100A1

公开(公告)日：2009-11-12

申请号：US12317493

申请日：2008-12-23

Applicant: Paul A. Barsanti ,  Dirksen Bussiere ,  Stephen D. Harrison ,  Carla C. Heise ,  Johanna M. Jansen ,  Elisa Jazan ,  Timothy D. Machajewski ,  Christopher McBride ,  William R. McCrea, JR. ,  Simon Ng ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Keith B. Pfister ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia M. Shafer ,  Joel B. Silver ,  Allan S. Wagman ,  Marion Wiesmann ,  Kelly Wayman

Inventor： Paul A. Barsanti ,  Dirksen Bussiere ,  Stephen D. Harrison ,  Carla C. Heise ,  Johanna M. Jansen ,  Elisa Jazan ,  Timothy D. Machajewski ,  Christopher McBride ,  William R. McCrea, JR. ,  Simon Ng ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Keith B. Pfister ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia M. Shafer ,  Joel B. Silver ,  Allan S. Wagman ,  Marion Wiesmann ,  Kelly Wayman

IPC: A61K31/5377 ,  A61K31/497 ,  A61K31/4709

CPC classification number: C07D401/04 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/52 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D453/02 ,  C07D453/06 ,  C07D471/04

Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Abstract translation: 提供了抑制各种酶和治疗各种病症的方法，其包括向受试者施用结构I或IB的化合物，其药学上可接受的盐，其互变异构体或互变异构体的药学上可接受的盐。 具有结构I和IB的化合物具有以下结构并具有本文所述的变量。 这些化合物可用于制备用于抑制各种酶的药物，并用于治疗由这些酶介导的病症。

公开(公告)号：US07470709B2

公开(公告)日：2008-12-30

申请号：US10644055

申请日：2003-08-19

Applicant: Paul A. Barsanti ,  Dirksen Bussiere ,  Stephen D. Harrison ,  Carla C. Heise ,  Johanna M. Jansen ,  Elisa Jazan ,  Timothy D. Machajewski ,  Christopher McBride ,  William R. McCrea, Jr. ,  Simon Ng ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Keith B. Pfister ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia M. Shafer ,  Joel B. Silver ,  Allan S. Wagman ,  Marion Wiesmann ,  Kelly Wayman

Inventor： Paul A. Barsanti ,  Dirksen Bussiere ,  Stephen D. Harrison ,  Carla C. Heise ,  Johanna M. Jansen ,  Elisa Jazan ,  Timothy D. Machajewski ,  Christopher McBride ,  William R. McCrea, Jr. ,  Simon Ng ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Keith B. Pfister ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia M. Shafer ,  Joel B. Silver ,  Allan S. Wagman ,  Marion Wiesmann ,  Kelly Wayman

IPC: A61K31/47

CPC classification number: C07D401/04 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/52 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D453/02 ,  C07D453/06 ,  C07D471/04

Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Abstract translation: 提供了抑制各种酶和治疗各种病症的方法，其包括向受试者施用结构I或IB的化合物，其药学上可接受的盐，其互变异构体或互变异构体的药学上可接受的盐。 具有结构I和IB的化合物具有以下结构并具有本文所述的变量。 这些化合物可用于制备用于抑制各种酶的药物，并用于治疗由这些酶介导的病症。

公开(公告)号：US20050203101A1

公开(公告)日：2005-09-15

申请号：US10839793

申请日：2004-05-05

Applicant: Paul Barsanti ,  Dirksen Bussiere ,  Stephen Harrison ,  Carla Heise ,  Johanna Jansen ,  Elisa Jazan ,  Timothy Machajewski ,  Christopher McBride ,  William McCrea ,  Simon Ng ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Keith Pfister ,  Savithri Ramurthy ,  Paul Renhowe ,  Cynthia Shafer ,  Joel Silver ,  Allan Wagman ,  Marion Wiesmann ,  Kelly Wayman

Inventor： Paul Barsanti ,  Dirksen Bussiere ,  Stephen Harrison ,  Carla Heise ,  Johanna Jansen ,  Elisa Jazan ,  Timothy Machajewski ,  Christopher McBride ,  William McCrea ,  Simon Ng ,  Zhi-Jie Ni ,  Sabina Pecchi ,  Keith Pfister ,  Savithri Ramurthy ,  Paul Renhowe ,  Cynthia Shafer ,  Joel Silver ,  Allan Wagman ,  Marion Wiesmann ,  Kelly Wayman

IPC: A61K31/4375 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/52 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D453/02 ,  C07D453/06 ,  C07D471/04 ,  C07D43/14

CPC classification number: C07D401/04 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/52 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D453/02 ,  C07D453/06 ,  C07D471/04

Abstract: Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.

Abstract translation: 治疗癌症的方法包括使癌细胞与4-氨基-5-氟-3-（5-哌嗪-1-基-1H-苯并咪唑-2-基）喹啉-2（1H） - 酮，4-氨基-5- 5-氟-3- [5-（4-甲基-4-氧代哌嗪-1-基）-1H-苯并咪唑-2-基]喹啉-2（1H） - 酮，其互变异构体，其药学上可接受的盐，药学上可接受的 其互变异构体的盐或其混合物。

公开(公告)号：US20120225861A1

公开(公告)日：2012-09-06

申请号：US13453202

申请日：2012-04-23

Applicant: James C. Sutton ,  Marion Wiesmann ,  Weibo Wang ,  Mika Lindvall ,  Jiong Lan ,  Savithri Ramurthy ,  Anu Sharma ,  Elizabeth J. Mieuli ,  Liana M Klivansky ,  William Lenahan ,  Susan Kaufman ,  Hong Yang ,  Simon C. Ng ,  Keith Pfister ,  Allan S. Wagman ,  Victoria Sung ,  Martin Sendzik

Inventor： James C. Sutton ,  Marion Wiesmann ,  Weibo Wang ,  Mika Lindvall ,  Jiong Lan ,  Savithri Ramurthy ,  Anu Sharma ,  Elizabeth J. Mieuli ,  Liana M Klivansky ,  William Lenahan ,  Susan Kaufman ,  Hong Yang ,  Simon C. Ng ,  Keith Pfister ,  Allan S. Wagman ,  Victoria Sung ,  Martin Sendzik

IPC: A61K31/4439 ,  C07D413/14 ,  A61K31/4545 ,  A61K31/5377 ,  C07D417/14 ,  A61P35/02 ,  A61P35/00 ,  A61P19/10 ,  A61P19/02 ,  A61P9/10 ,  A61P13/12 ,  C07D413/12 ,  A61K31/55

CPC classification number: C07D413/12 ,  C07D417/12

Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

Abstract translation: 公开了苯并恶唑和苯并噻唑化合物及其立体异构体，互变异构体，溶剂合物，氧化物，酯和前药及其药学上可接受的盐。 还公开了单独或与至少一种另外的治疗剂组合的化合物与药学上可接受的载体的组合，以及化合物单独或与至少一种另外的治疗剂组合的用途。 这些实施方案可用于抑制细胞增殖，抑制肿瘤的生长和/或复分解，治疗或预防癌症，治疗或预防退行性骨疾病如类风湿性关节炎和/或抑制分子如CSF-1R。

公开(公告)号：US07825132B2

公开(公告)日：2010-11-02

申请号：US10983174

申请日：2004-11-05

Applicant: Shaopei Cai ,  Joyce Chou ,  Eric Harwood ,  Carla C. Heise ,  Timothy D. Machajewski ,  David Ryckman ,  Xiao Shang ,  Marion Wiesmann ,  Shuguang Zhu

Inventor： Shaopei Cai ,  Joyce Chou ,  Eric Harwood ,  Carla C. Heise ,  Timothy D. Machajewski ,  David Ryckman ,  Xiao Shang ,  Marion Wiesmann ,  Shuguang Zhu

IPC: A61K31/47 ,  A01N43/40

CPC classification number: A61K31/496

Abstract: Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

Abstract translation: 提供了抑制成纤维细胞生长因子受体3并治疗由成纤维细胞生长因子受体3介导的各种病症的方法，其包括向受试者施用结构I的化合物，其药学上可接受的盐，其互变异构体或其药学上可接受的盐 互变异构体 具有结构I的化合物具有以下结构，并且具有本文所述的变量。 这样的化合物可以用于制备用于抑制成纤维细胞生长因子受体3的药物，并且用于治疗由成纤维细胞生长因子受体3如多发性骨髓瘤介导的病症。

公开(公告)号：US20080045528A1

公开(公告)日：2008-02-21

申请号：US11737069

申请日：2007-04-18

Applicant: James Sutton ,  Marion Wiesmann ,  Weibo Wang ,  Mika Lindvall ,  Jiong Lan ,  Savithri Ramurthy ,  Anu Sharma ,  Elizabeth Mieuli ,  Liana Klivansky ,  William Lenahan ,  Susan Kaufman ,  Hong Yang ,  Simon Ng ,  Keith Pfister ,  Allan Wagman ,  Victoria Sung ,  Martin Sendzik

Inventor： James Sutton ,  Marion Wiesmann ,  Weibo Wang ,  Mika Lindvall ,  Jiong Lan ,  Savithri Ramurthy ,  Anu Sharma ,  Elizabeth Mieuli ,  Liana Klivansky ,  William Lenahan ,  Susan Kaufman ,  Hong Yang ,  Simon Ng ,  Keith Pfister ,  Allan Wagman ,  Victoria Sung ,  Martin Sendzik

IPC: A61K31/535 ,  A61K31/44 ,  A61K31/445 ,  C07D211/00 ,  C07D413/00 ,  C07D417/00 ,  C07D401/00 ,  A61P43/00 ,  A61K31/497

CPC classification number: C07D413/12 ,  C07D417/12

Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

Abstract translation: 公开了苯并恶唑和苯并噻唑化合物及其立体异构体，互变异构体，溶剂合物，氧化物，酯和前药及其药学上可接受的盐。 还公开了单独或与至少一种另外的治疗剂组合的化合物与药学上可接受的载体的组合，以及化合物单独或与至少一种另外的治疗剂组合的用途。 这些实施方案可用于抑制细胞增殖，抑制肿瘤的生长和/或复分解，治疗或预防癌症，治疗或预防退行性骨疾病如类风湿性关节炎和/或抑制分子如CSF-1R。

公开(公告)号：US08710048B2

公开(公告)日：2014-04-29

申请号：US13453202

申请日：2012-04-23

Applicant: James C. Sutton ,  Marion Wiesmann ,  Weibo Wang ,  Mika Lindvall ,  Jiong Lan ,  Savithri Ramurthy ,  Anu Sharma ,  Elizabeth J. Mieuli ,  Liana M. Klivansky ,  William Lenahan ,  Susan Kaufman ,  Hong Yang ,  Simon C. Ng ,  Keith B. Pfister ,  Allan S. Wagman ,  Victoria Sung ,  Martin Sendzik

Inventor： James C. Sutton ,  Marion Wiesmann ,  Weibo Wang ,  Mika Lindvall ,  Jiong Lan ,  Savithri Ramurthy ,  Anu Sharma ,  Elizabeth J. Mieuli ,  Liana M. Klivansky ,  William Lenahan ,  Susan Kaufman ,  Hong Yang ,  Simon C. Ng ,  Keith B. Pfister ,  Allan S. Wagman ,  Victoria Sung ,  Martin Sendzik

IPC: A61K31/4439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/55 ,  C07D413/14 ,  C07D417/14 ,  C07D413/12 ,  A61P35/02 ,  A61P35/00 ,  A61P19/10 ,  A61P9/10 ,  A61P13/12

CPC classification number: C07D413/12 ,  C07D417/12

Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

Abstract translation: 公开了苯并恶唑和苯并噻唑化合物及其立体异构体，互变异构体，溶剂合物，氧化物，酯和前药及其药学上可接受的盐。 还公开了单独或与至少一种另外的治疗剂组合的化合物与药学上可接受的载体的组合，以及化合物单独或与至少一种另外的治疗剂组合的用途。 这些实施方案可用于抑制细胞增殖，抑制肿瘤的生长和/或复分解，治疗或预防癌症，治疗或预防退行性骨疾病如类风湿性关节炎和/或抑制分子如CSF-1R。